Literature DB >> 27549029

Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.

Carolyn T Thorpe1,2, Nicole R Fowler3,4, Katherine Harrigan5, Xinhua Zhao5,6,7, Yihuang Kang7, Joseph T Hanlon5,6,7, Walid F Gellad6,8, Loren J Schleiden5,6, Joshua M Thorpe5,6.   

Abstract

OBJECTIVES: To examine racial and ethnic differences in initiation and time to discontinuation of antidementia medication in Medicare beneficiaries.
DESIGN: Retrospective cohort study.
SETTING: Secondary analysis of 2009-10 enrollment, claims, and Part D prescription data for a 10% national sample of U.S. Medicare fee-for-service beneficiaries. PARTICIPANTS: Beneficiaries aged 65 and older with Alzheimer's disease or related dementia (ADRD) before 2009 and no fills for antidementia medications in the first half of 2009 (N = 84,043). MEASUREMENTS: Initiation was defined as having one or more fills for antidementia medication in the second half of 2009 and discontinuation as a gap in coverage of 30 days or more during the year after initiation. The Andersen Behavioral Model was used to guide covariate selection.
RESULTS: Overall, 3,481 (4.1%) of previous nonusers initiated antidementia medication in the second half of 2009. Of those initiating one drug class (acetylcholinesterase inhibitors (AChEIs) or memantine), 9% later added the other class, and 2% switched classes. Of initiators, 23% discontinued within 1 month, and 62% discontinued within 1 year. Hispanic beneficiaries were more likely than white beneficiaries to initiate (adjusted odds ratio = 1.25, 95% confidence interval (CI) = 1.10-1.41). Black and white beneficiaries did not differ in likelihood of initiation. Hispanic (adjusted hazard ratio (aHR) = 1.56, 95% CI = 1.34-1.82) and black (aHR = 1.25, 95% CI = 1.08-1.44) beneficiaries discontinued at a faster rate than white beneficiaries.
CONCLUSION: Initiation of antidementia medications was no different in black and white beneficiaries and more likely in Hispanic beneficiaries; black and Hispanic beneficiaries discontinued at a faster rate. More research into reasons explaining these differences is needed.
© 2016, Copyright the Authors Journal compilation © 2016, The American Geriatrics Society.

Entities:  

Keywords:  Medicare; antidementia medications; dementia; health disparities; medication discontinuation

Mesh:

Substances:

Year:  2016        PMID: 27549029      PMCID: PMC5026892          DOI: 10.1111/jgs.14403

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  43 in total

1.  Has Medicare Part D reduced racial/ethnic disparities in prescription drug use and spending?

Authors:  Elham Mahmoudi; Gail A Jensen
Journal:  Health Serv Res       Date:  2013-09-18       Impact factor: 3.402

2.  Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Authors:  Lisa Mucha; Sara Shaohung; Brian Cuffel; Thomas McRae; Tami L Mark; Megan Del Valle
Journal:  J Manag Care Pharm       Date:  2008-06

3.  Cross-cultural differences in dementia: the Sociocultural Health Belief Model.

Authors:  Philip Sayegh; Bob G Knight
Journal:  Int Psychogeriatr       Date:  2012-12-14       Impact factor: 3.878

4.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

5.  2015 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2015-03       Impact factor: 21.566

6.  Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries.

Authors:  Ilene H Zuckerman; Priscilla T Ryder; Linda Simoni-Wastila; Thomas Shaffer; Masayo Sato; Lirong Zhao; Bruce Stuart
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2008-09       Impact factor: 4.077

7.  Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations.

Authors:  Adrienne M Gilligan; Daniel C Malone; Terri L Warholak; Edward P Armstrong
Journal:  Am J Geriatr Pharmacother       Date:  2012-10

8.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

9.  Care patterns in Medicare and their implications for pay for performance.

Authors:  Hoangmai H Pham; Deborah Schrag; Ann S O'Malley; Beny Wu; Peter B Bach
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

Review 10.  Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Authors:  Parminder Raina; Pasqualina Santaguida; Afisi Ismaila; Christopher Patterson; David Cowan; Mitchell Levine; Lynda Booker; Mark Oremus
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

View more
  15 in total

1.  Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Authors:  Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant
Journal:  Alzheimers Dement       Date:  2018-12-13       Impact factor: 21.566

2.  Risk Factors for Cardiovascular Events in Patients on Antidementia Medications.

Authors:  Meiqi He; James M Stevenson; Yuting Zhang; Inmaculada Hernandez
Journal:  Am J Alzheimers Dis Other Demen       Date:  2020 Jan-Dec       Impact factor: 2.035

Review 3.  [Tapering of antidementia drugs, antidepressants and antipsychotics in elderly patients : When possible, when not?]

Authors:  K Hager; T Temps; O Krause
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-06-06       Impact factor: 0.840

4.  Dementia Care in Diverse Older Adults in the U.S. Deep South and the Rest of the United States.

Authors:  Maria Pisu; Roy C Martin; Liang Shan; Giovanna Pilonieta; Richard E Kennedy; Gabriela Oates; Young-Il Kim; David S Geldmacher
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

5.  Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.

Authors:  Carolyn W Zhu; Judith Neugroschl; Lisa L Barnes; Mary Sano
Journal:  Alzheimers Dement       Date:  2022-02-25       Impact factor: 16.655

6.  Racial and Ethnic Disparities in Serious Psychological Distress Among Those With Alzheimer's Disease and Related Dementias.

Authors:  Priscilla Novak; Jun Chu; Mir M Ali; Jie Chen
Journal:  Am J Geriatr Psychiatry       Date:  2019-08-15       Impact factor: 4.105

7.  Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.

Authors:  Douglas Barthold; Geoffrey Joyce; Patricia Ferido; Emmanuel F Drabo; Zachary A Marcum; Shelly L Gray; Julie Zissimopoulos
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

8.  Discontinuation of Statins in Veterans Admitted to Nursing Homes near the End of Life.

Authors:  Carolyn T Thorpe; Florentina E Sileanu; Maria K Mor; Xinhua Zhao; Sherrie Aspinall; Mary Ersek; Sydney Springer; Joshua D Niznik; Michelle Vu; Loren J Schleiden; Walid F Gellad; Jacob Hunnicutt; Joshua M Thorpe; Joseph T Hanlon
Journal:  J Am Geriatr Soc       Date:  2020-08-12       Impact factor: 5.562

Review 9.  Impact of dementia: Health disparities, population trends, care interventions, and economic costs.

Authors:  María P Aranda; Ian N Kremer; Ladson Hinton; Julie Zissimopoulos; Rachel A Whitmer; Cynthia Huling Hummel; Laura Trejo; Chanee Fabius
Journal:  J Am Geriatr Soc       Date:  2021-07       Impact factor: 7.538

10.  Healthcare utilization of Mexican-American Medicare beneficiaries with and without Alzheimer's disease and related dementias.

Authors:  Brian Downer; Soham Al Snih; Mukaila Raji; Lin-Na Chou; Yong-Fang Kuo; Kyriakos S Markides; Kenneth J Ottenbacher
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.